论文部分内容阅读
目的研究中药治疗肝腹水领域的专利文献,为该领域的新药研发提供文献参考。方法以中国专利数据库、SFDA网站为检索源,以肝腹水、肝硬化和中药为关键词,对1991—2017年公布或公开的专利申请进行检索,再通过人工降噪的方法确定最终肝腹水文献,以IPC分类、申请人类别、重点申请人、法律状态等特征进行分析。结果检索到肝腹水有关的中医药专利文献共计242篇,主要集中在A61大类中,有效专利占总专利数的12%,失效专利占到总专利数的65%,专利申请的主体以自然人为主,从专利申请增长率方面来看,该领域的专利申请趋势在逐年增大,但是截止目前为止还没有专门针对该类疾病的上市中成药,处于市场空白期。结论治疗肝腹水领域的有效专利数少,成果产业化低,目前在已上市中成药中还没有专门针对该类疾病药品,所以研制出具有自主知识产权治疗肝腹水的中药新药具有广阔的市场前景。
Objective To study the patent literature of traditional Chinese medicine in the treatment of hepatic ascites and provide references for the research and development of new drugs in this field. Methods The Chinese patent database and SFDA website were used as the search sources. The key words of liver ascites, liver cirrhosis and traditional Chinese medicine were searched. The patent applications published or published in 1991 to 2017 were searched, and then the final hepatic ascites literature was determined by artificial noise reduction , With IPC classification, the applicant category, key applicants, legal status and other characteristics for analysis. Results A total of 242 TCM patents were retrieved from liver ascites, which mainly concentrated in A61 categories. The effective patents accounted for 12% of the total patents and the invalid patents accounted for 65% of the total patents. The subjects of the patent applications were natural People-oriented, from the patent application rate of growth point of view, the trend of patent applications in the field is increasing year by year, but so far there is no specific proprietary Chinese medicines listed for such diseases in the market blank period. Conclusions The number of effective patents in the treatment of hepatic ascites is low and the industrialization of the results is low. At present, there are no specific drugs for these diseases in the listed proprietary Chinese medicines, so the development of new Chinese medicine with independent intellectual property rights for the treatment of hepatic ascites has a broad market prospect .